NASDAQ: AUGXAugmedix Inc Stock
$1.50-0.05 (-3.23%)
Updated Mar 24, 2023
AUGX Price
$1.50
Fair Value Price
N/A
Market Cap
$56.15M
52 Week Low
$1.01
52 Week High
$3.17
P/E
-2.24x
P/B
8.7x
P/S
1.89x
PEG
N/A
Dividend Yield
N/A
Revenue
$28.76M
Earnings
-$24.32M
Gross Margin
44.7%
Operating Margin
-77.92%
Profit Margin
-84.6%
Debt to Equity
4.76
Operating Cash Flow
-$18M
Beta
1.09
Next Earnings
Mar 27, 2023
Ex-Dividend
N/A
Next Dividend
N/A
AUGX Overview
Augmedix, Inc. provides remote medical documentation solutions and live clinical support services in the U.S. Its platforms (Augmedix Live and Augmedix Notes) offer pre-visit documentation (pre-charting and digitization of previous records/patient history), during-visit documentation, and after-visit summaries and post-visit documentation. Clinicians cab access its applications through mobile devices. The company was founded in 2013 and is headquartered in San Francisco, CA.
Zen Score
–
Industry Average (29)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how AUGX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AUGX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
AUGX is poor value based on its book value relative to its share price (8.7x), compared to the US Health Information Services industry average (3.47x)
P/B vs Industry Valuation
AUGX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more AUGX due diligence checks available for Premium users.
Be the first to know about important AUGX news, forecast changes, insider trades & much more!
AUGX News
Valuation
AUGX fair value
Fair Value of AUGX stock based on Discounted Cash Flow (DCF)
Price
$1.50
Fair Value
$2.32
Undervalued by
35.38%
AUGX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
AUGX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.24x
Industry
3.36x
Market
21.37x
AUGX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
8.7x
Industry
3.47x
AUGX is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
AUGX's financial health
Profit margin
Revenue
$7.9M
Net Income
-$5.5M
Profit Margin
-69.8%
AUGX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
AUGX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$37.1M
Liabilities
$30.7M
Debt to equity
4.76
AUGX's short-term assets ($32.96M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AUGX's short-term assets ($32.96M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AUGX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.5M
Investing
-$201.0k
Financing
$4.0k
AUGX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
AUGX vs Health Information Service Stocks
Augmedix Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.